AR063723A1 - 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios - Google Patents
5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatoriosInfo
- Publication number
- AR063723A1 AR063723A1 ARP070104812A ARP070104812A AR063723A1 AR 063723 A1 AR063723 A1 AR 063723A1 AR P070104812 A ARP070104812 A AR P070104812A AR P070104812 A ARP070104812 A AR P070104812A AR 063723 A1 AR063723 A1 AR 063723A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- heterocyclyl
- sulfonyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Abstract
Reivindicación 1: Un compuesto de Fórmula (1): o una sal, estereoisómero, tautómero, forma cristalina, polimorfo, amorfo, solvato, hidrato, éster, profármaco o metabolito de éste, en el cual: A está ausente o es alquilo C1-8; Y es cicloalquilo C3- 14, arilo, heterociclo o heteroarilo cada uno sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados de alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-8, haloalquilo C1-8, haloalcoxi C1-8, halógeno, hidroxi o amino, donde el heteroarilo no es tiazol; Z es R1-amino-carbonilo o heterociclil-carbonilo; R1 es un sustituyente seleccionado de hidrógeno, alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, hidroxi, hidroxi-alquilo C1-8, amino-alquilo C1-8, alquil- amino C1-8-alquilo C1-8, cicloalquil C3-14-oxi o heteroarilo; R101 es uno o dos sustituyentes seleccionados cada uno de hidrógeno, halógeno o hidroxi; R200 es un sustituyente seleccionado de hidrógeno, R2-alquilo C1-8, R3-alcoxi C1-8, R4-amino, R4- amino-alquilo C1-8, R4-amino-carbonilo, R4-amino-alquil-carbonilo C1-8, R4-amino-sulfonilo, R4-amino-aIquil-sulfonilo C1-8, R5-cicloalquilo C3-14, R5-cicloalquil C3-14-alquilo C1-8, R5-arilo, R5-aril-alquilo R5-heterociclilo, R5-heterociclil-oxi, R5- heterociclil-carbonilo, R5-heterociclil-sulfonilo, R5-heterociclil-alquilo C1-8, R5-heteroarilo o R5-heteroaril-alquilo C1-8; en forma alternativa, R200 es un anillo seleccionado de heterociclilo o heteroarilo fusionado sobre dos átomos de carbono adyacentes del anillo fenilo de la Fórmula (1) para formar un anillo heteroarilo o heterociclilo bicíclico sustituído con R5; R2 es uno, dos o tres sustituyentes opcionales seleccionados cada uno de halógeno, hidroxi, alcoxi C1-8, carboxi, amino- carbonilo, alquil-amino C1-8-carbonilo, amino-amino-carbonilo, alquil-amino C1-8-amino-carbonilo, alquil-sulfonilo C1-8, amino-sulfonilo, alquil-aminosulfonilo C1-8, alquil C1-8-carbonil-amino-sulfonilo, alquil C1-8-sulfonil-amino-carbonilo, R5- heterociclil-carbonilo, R5-heterociclil-amino-carbonilo o R5-heterociclil-sulfonilo; R3 es uno, dos o tres sustituyentes opcionales seleccionados cada uno de halógeno, hidroxi, alcoxi C1-8, amino, aquil-amino C1-8 o R5-heterociclilo; R4 es dos sustituyentes seleccionados cada uno de hidrógeno, alquilo C1-8, alcoxi C1-8-alquilo C1-8, hidroxi-alquilo C1-8, amino-alquilo C1-8, alquilamino C1-8-alquilo C1-8, amino-alquil-carbonilo C1-8, alquil-amino C1-8 alquil-carbonilo C1-8, alquil- sulfonilo C1-8, alquil C1-8-sulfonil-alquilo C1-8, cicloalquilo C3-14, R5-heterociclilo o R5-heterociclil-alquilo C1-8; R5 es uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, oxo, carboxi, R6-alquilo C1- 8, R6-alcoxi C1-8, amino, alquil-amino C1-8, alquil-sulfonilo C1-8, amino-sulfonilo, alquil-amino-sulfonilo C1-8, R6-alquil-carbonilo C1-8, alcoxi-carbonilo C1-8, haloalquilo C1-8, halo-alquil-carbonilo C1-8 o halo-alquil-sulfonilo C1-8; y R6 es uno, dos, tres, cuatro o cinco sustituyentes seleccionados cada uno de hidrógeno, halógeno, hidroxi, amino, alquil-amino C1-8, alcoxi C1-8, carboxi, alcoxi-carbonilo C1-8, alquil-sulfonilo C1-8, alquil C1-8-sulfonil-amino-carbonilo, arilo o heterociclilo, donde el heterociclilo está sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados cada uno de oxo o alquilo C1-8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85552306P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063723A1 true AR063723A1 (es) | 2009-02-11 |
Family
ID=39144475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104812A AR063723A1 (es) | 2006-10-31 | 2007-10-30 | 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080114007A1 (es) |
| AR (1) | AR063723A1 (es) |
| CL (1) | CL2007003163A1 (es) |
| WO (1) | WO2008055013A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642270B2 (en) * | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| BRPI1015135B1 (pt) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos |
| US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| US8518214B2 (en) | 2011-07-18 | 2013-08-27 | Nalco Company | Debonder and softener compositions |
| SI3196202T1 (sl) | 2011-09-02 | 2019-05-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji PI3K |
| CA2851640A1 (en) | 2011-10-20 | 2013-04-25 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| BR112015000372B1 (pt) | 2012-07-12 | 2020-07-28 | Nissan Chemical Corporation | composto de amida substituído por oxima e agente de controle de peste |
| WO2015019037A1 (en) * | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| CN117736209A (zh) | 2015-02-27 | 2024-03-22 | 因赛特控股公司 | Pi3k抑制剂的盐及其制备方法 |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| BR112021008675A2 (pt) | 2018-11-05 | 2021-08-10 | Syngenta Participations Ag | compostos de azole-amida pesticidamente ativos |
| WO2020191503A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders |
| CN112457309B (zh) * | 2020-09-01 | 2023-03-17 | 扬州工业职业技术学院 | 一种苯基取代吡啶并嘧啶胺类化合物及其作为抗菌药物的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| EE200200506A (et) * | 2000-03-06 | 2004-02-16 | Warner-Lambert Company | 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid |
| CA2536964A1 (en) * | 2003-04-25 | 2004-11-11 | Ortho-Mcneil Pharmaceutical, Inc. | C-fms kinase inhibitors |
| US7642270B2 (en) * | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| CN101300258A (zh) * | 2005-09-14 | 2008-11-05 | 詹森药业有限公司 | 作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类 |
-
2007
- 2007-10-19 WO PCT/US2007/081930 patent/WO2008055013A2/en active Application Filing
- 2007-10-19 US US11/875,294 patent/US20080114007A1/en not_active Abandoned
- 2007-10-30 AR ARP070104812A patent/AR063723A1/es unknown
- 2007-10-31 CL CL200703163A patent/CL2007003163A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008055013A3 (en) | 2009-01-22 |
| US20080114007A1 (en) | 2008-05-15 |
| CL2007003163A1 (es) | 2008-06-27 |
| WO2008055013A2 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063723A1 (es) | 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR082562A1 (es) | Derivados de isoxazolina como agentes antiparasitarios | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| ES2653419T3 (es) | Pirazolopirimidinilamino-indazoles sustituidos | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR087148A1 (es) | Imidazopiridazinas | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CU20080165A7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |